Newron banks $25.5m before Xadago's FDA go/no-go
This article was originally published in Scrip
Executive Summary
With its stock riding close to a seven-year high, and well ahead of an FDA decision on its partnered Parkinson's disease drug, Xadago (safinamide), CNS specialist Newron has raised $25.5m gross from an international group of institutional investors. That gives the Milan-based company around $23-24m to put into its unpartnered earlier-stage pipeline, assuming placing discounts of 5-8%.